The aim of this study was to assess in healthy subjects the safety , tolerability , pharmacokinetics , and pharmacodynamics of ponesimod , an oral selective sphingosine-@-phosphate receptor @ ( S@P@ ) modulator in development for multiple sclerosis , by using an uptitration scheme up to supratherapeutic doses .